Clinical trials: Immune System Tolerance
Cow Milk Allergy
Growth, Safety and Tolerance of a Hydrolyzed Protein Infant Formula
This is a single arm, open label, multicenter intervention trial to evaluate growth parameters, cow's milk related symptoms, gastrointestinal tolerance and safety in infants with cow's milk allergy receiving a hydrolyzed protein…
- Trial name
- STORY (NCT05618704)
- Testing
- Hydrolyzed protein infant formula
- Where
- Poland
- Volunteers
- 69 people
- Sponsor
- Nutricia Research
Advanced Solid Tumor or Hematologic Tumor
A Phase I Study of TQB728 Tablets on Tolerance and Pharmacokinetics
This is a open-label, phase I study to evaluate tolerance and pharmacokinetics of TQB3728 tablets in subjects with advanced solid tumor or hematologic tumor.
- Trial name
- NCT04523285
- Testing
- TQB3728
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Conditions Influencing Health Status
Effects of Probiotics in Immune System of Healthy Adults
The present report describes the design of a clinical trial performed on healthy adult individuals to check whether the daily intake of the new Hero strains contribute to intestinal colonization, under safe and tolerable…
- Trial name
- SETOPROB (NCT01479543)
- Testing
- Probiotic CNCM I-4034, Probiotic CNCM I-4035, Probiotic CNCM I-4036
- Where
- 4 sites in Spain
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- Hero Institute for Infant Nutrition
Influenza
Evaluation the Safety and Tolerance of GP681 Tablets in Healthy Subjects
Influenza (influenza for short) is an acute respiratory infectious disease caused by influenza virus. The symptoms of the disease range from mild, moderate to severe, and severe cases require hospitalization and may die.
- Trial name
- NCT04729764
- Testing
- GP681 Tablet
- Where
- China
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Diabetes Mellitus, Type 2
A Study to Determine Acute (After First Dose) and Chronic (After 28 Days) Effects of Empagliflozin (BI 10773) on Pre and Postprandial Glucose Homeostasis in Patients With Impaired Glucose Tolerance and Type 2 Diabetes Mellitus and Healthy Subjects
An open-label, phase II study to assess the acute and chronic effects of empagliflozin (BI 10773)on fasting and postprandial glucose homeostasis in patients with IGT and type 2 diabetes mellitus and assess the acute effects of…
- Trial name
- NCT01248364
- Testing
- BI 10773
- Where
- 3 sites in Austria, Germany and 1 more
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Carcinoma, Non-Small-Cell Lung, Lung Neoplasm
An Open Label Study of a Peptide Vaccine in Patients With Stage IIb or IIIa Non-Small Cell Lung Cancer
EP2101 is a new cancer vaccine containing 10 different peptide antigens. The vaccine is designed to activate the immune system to develop a response against tumor cells in order to delay or prevent the recurrence of cancer.
- Trial name
- NCT00054899
- Testing
- EP2101
- Where
- 8 sites in United States
- Volunteers
- 18 people
- Sponsor
- Epimmune
Alzheimer Disease
Study of Azeliragon in Patients With Mild Alzheimer's Disease and Impaired Glucose Tolerance
This is a study to evaluate the efficacy and safety of azeliragon in patients with mild Alzheimer's disease and impaired glucose tolerance.
- Trial name
- Elevage (NCT03980730)
- Testing
- Azeliragon
- Where
- 33 sites in United States, Canada
- Volunteers
- 43 people
- Sponsor
- vTv Therapeutics
Colon Cancer Adenocarcinoma
A Phase Ib/II Study to Evaluate HLX43 Combined With HLX07 or Serplulimab in Patients With Advanced or Metastatic Colorectal Cancer
This study is a phase Ib/II study to evaluate the efficacy, safety and tolerance of HLX43 combined with HLX07 or Serplulimab in patients with advanced or metastatic colorectal cancer failed or intolerance to standard first-line…
- Trial name
- NCT07358585
- Testing
- HLX43 dose 1 + HLX07, HLX43 dose 2 + HLX07, HLX43 dose 3 + Serplulimab
- Where
- China
- Volunteers
- 126 people
- Sponsor
- Shanghai Henlius Biotech
Advanced Solid Tumor
A Study Evaluating the Safety, Tolerance and Anti-tumor Activity of HBM1020 in Subjects With Advanced Solid Tumors
This is a study to evaluate the safety and tolerability of the study drug HBM1020 which contains two parts. Part 1 will enroll solid tumor participants and Part 2 will enroll renal cell carcinoma (RCC) and colorectal…
- Trial name
- NCT05824663
- Testing
- HBM1020
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Harbour BioMed US, Inc.
T2DM (Type 2 Diabetes Mellitus)
Safety, Tolerance and Pharmacokinetics of THR-1442 in Chinese Healthy Subjects
The purpose of this study was to investigate Safety, tolerability and pharmacokinetics in Chinese healthy subjects.
- Trial name
- NCT05369078
- Testing
- THR-1442 20mg Single dose, THR-1442 20mg Multiple dose group
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Newsoara Biopharma Co., Ltd.
Safety Issues, Tolerance
Phase I Study to Evaluate KP405 in Healthy and Parkinson's Disease Patients
This study will explore the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of KP405 as a potential new treatment for Parkinson's disease.
- Trial name
- NCT06189170
- Testing
- KP405
- Where
- United Kingdom
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Kariya Pharmaceuticals
Renal Cell Carcinoma
A Study of HS-10516 in Patients With Advanced Clear Cell Renal Cell Carcinoma
The aim of the Phase Ia portion is to identify the maximum tolerated dose or maximum acceptable dose MTD/MAD of HS-10516. The phase Ib portion will evaluate the preliminary efficacy of HS-10516 in ccRCC.
- Trial name
- NCT06049030
- Testing
- HS-10516
- Volunteers
- 190 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Gastro-Intestinal Tolerance
Tolerance of an Oral Nutritional Supplement(ONS)
The objective of this study is to capture information on gastrointestinal tolerance (GI) of an oral nutritional supplement containing a new protein blend in healthy children aged ≥ 3 to ≤ 10 years.
- Trial name
- NCT01782456
- Testing
- Study Oral Nutritional Supplement
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Abbott Nutrition
Aging Well
Gut Health, Inflammation, Hormones
Pilot exploratory study on the effect of a Bifidobacterium breve extract, as VMK223, on plasma inflammatory markers, saliva hormones, gut microbiota and tolerance in females over 50years old.
- Trial name
- NCT04267731
- Testing
- VMK223, Cellulose
- Where
- United Kingdom
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Vemico Ltd.
Impaired Glucose Tolerance
Investigation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LIM-0705 in Male Subjects With Impaired Glucose Tolerance
LIM-0705 will gain results on the effects of LIM-0705 on Male Subjects with Impaired Glucose Tolerance
- Trial name
- LIM (NCT01093677)
- Testing
- LIM-0705
- Volunteers
- 30 people
- Sponsor
- Limerick BioPharma
Breast Cancer, Ovarian Cancer
A Study of BL0175 Injection in Postmenopausal Female Adults With HR-positive, Locally Advanced or Metastatic Cancer
The goal of this clinical trial is to learn if the investigational drug BL0175 works to treat adult postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor (HER2)-negative locally advanced…
- Conditions
- Breast Cancer, Ovarian Cancer, Endometrial Cancer
- Trial name
- NCT06738966
- Testing
- BL0175
- Where
- 2 sites in China
- Volunteers
- 9 people
- Sponsor
- Shanghai Best-Link Bioscience, LLC
Lipoprotein Disorder Disease
Safety and Tolerance of Increased Doses of HRS-5346 Tablets in Healthy Subjects
This is a randomized, double-blind, placebo-controlled phase I clinical study. The primary objective is to evaluate the safety, tolerability, PK, and PD of single- and multiple-dose HRS-5346 in healthy subjects, and to evaluate…
- Trial name
- NCT06441227
- Testing
- HRS-5346 tablets
- Where
- China
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Pulmonary Disease, Chronic Obstructive
Effect of Tiotropium (Spiriva) on Exercise Tolerance in COPD Patients
To investigate whether tiotropium (Spiriva) improves exercise endurance in patients with COPD
- Trial name
- NCT00274508
- Testing
- tiotropium bromide
- Where
- 28 sites in United States, Australia and 2 more
- Volunteers
- 261 people
- Sponsor
- Boehringer Ingelheim
Pea Proteins, Muscle Damage
Effects of Pea Proteins on Muscle Damage and Recovery
This study is a double-blind, randomized, placebo-controlled, crossover clinical trial of N=40 recreationally active men to be recruited a single investigational center in Ohio (i.e., The Center for Applied Health Sciences).
- Conditions
- Pea Proteins, Muscle Damage, Amino Acid Change
- Trial name
- NCT05657314
- Testing
- Active Comparator
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- The Center for Applied Health Sciences, LLC
Carcinoma, Non-Small-Cell Lung, Urothelial Carcinoma
A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors
This study will consider the safety and effectiveness of a study drug, CAN04, in combination with pembrolizumab, in the treatment of incurable or metastatic non-small-cell lung cancer (NSCLC), head and neck squamous cell…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Urothelial Carcinoma, Malignant Melanoma, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT04452214
- Testing
- CAN04, Pembrolizumab, Carboplatin
- Where
- 3 sites in United States
- Volunteers
- 19 people
- Sponsor
- Cantargia AB